FRENCH HOMEOPATHIC DRUGS COMPETITION
Competition in France between the two leading producers of homeopathic medicines, Boiron and Dolisos, has intensified, despite a 6.2 million franc ($1.1 million) loss posted by Dolisos for 1991.
Francois Levy, Dolisos' president, notes that the firm's operating earnings doubled last year and a new commercial offensive is in hand. Dolisos sales went up 7.8% last year to 550.8 million francs ($98.3 million) and gross earnings rose by 12.7% to 25.4 million francs. However, the self-financing gross margin fell back 12%.
The company shed 70 jobs last year, and is limiting its 1992 investment to 23 million francs, compared with the 55 million francs spent in 1991. Development of specialties is being stressed, and sales are expected to double in 1992 but account for only 4% of group sales.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze